In this edition of “Just a Phase,” we look at a phase 2 trial of vonoprazan as a therapy for nonerosive gastroesophageal reflux disease. The double-blind study looked at the effects of daily dosages on symptoms, and whether the drug could provide on-demand release at three different doses compared with placebo.
A potassium-competitive acid blocker (P-CAB), vonoprazan (Phathom) is used in Japan but is not approved in the United States.
Like proton pump inhibitors (PPIs), P-CABs reduce